Trerotola SO, et al. - In view of small trials reporting promising efficacy of paclitaxel-coated balloons in reducing access-related restenosis in hemodialysis patients, researchers performed this multicenter randomized trial to test the hypothesis that a drug-coated balloon would demonstrate superior effectiveness at 180 days and noninferior safety at 30 days when compared with conventional angioplasty for treatment of dysfunctional arteriovenous fistulas. Grafts, central venous stenoses, thrombosed fistulas, and immature fistulas were excluded. They found that paclitaxel-coated balloon–assisted angioplasty vs conventional angioplasty failed to meet the primary effectiveness end point at 180 days, however, both arms showed equivalent safety.